Adjuvant pembrolizumab (Keytruda, Merck) significantly improved overall survival in patients with clear cell renal cell carcinoma (ccRCC) at high risk for recurrence after surgery. This news, from the phase 3 KEYNOTE-564 study, was presented at the 2024 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (LBA359).
According to lead author Toni K. Choueiri, MD, the director of the Lank Center for GU Oncology at Dana-Farber Cancer Institute, in Boston, who presented the